News of Note—FluGen, Roswell Park Cancer Institute and The Vaccine Group

FluGen rounds up more cash, FDA awards a new orphan drug designation and The Vaccine Group forms.

> Madison, Wisconsin-based FluGen reeled in $5.5 million as it prepares for three tests on a universal flu vaccine candidate next year. Xconomy story

> The FDA awarded an orphan drug designation for a glioblastoma vaccine candidate developed at the Roswell Park Cancer Institute. Release

> A spinoff from the University of Plymouth dubbed The Vaccine Group formed to work on vaccines against pathogens such as avian influenza A, Ebola and Marburg viruses, MERS and SARS. Release


Suggested Articles

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.

GlaxoSmithKline’s vaccines unit has been a bright spot for the company, but its performance doesn’t make it immune to staff cuts.